Critical Care Pharmacist Attitudes and Perceptions of Neuromuscular Blocker Infusions in ARDS

  • John W. Devlin (Creator)
  • Sarah E. Train (Creator)
  • K. Burns (Creator)
  • Anthony Massaro (Creator)
  • Ting Ting Wu (Creator)
  • Timothy Castor (Creator)
  • John Vassaur (Creator)
  • Kavitha Selvan (Creator)
  • John P. Kress (Creator)
  • Brian L Erstad (Creator)
  • Karen Burns (Creator)
  • John Vassaur (Creator)
  • John P. Kress (Creator)



Background:Current critical care pharmacist (CCP) practices and perceptions related to neuromuscular infusion (NMBI) use for acute respiratory distress syndrome (ARDS) maybe different with the COVID-19 pandemic and the publication of 2020 NMBI practice guidelines.Objective:To evaluate CCP practices and perceptions regarding NMBI use for patients with moderate-severe ARDS.Methods:We developed, tested, and electronically administered a questionnaire (7 parent-, 42 sub-questions) to 409 American College of Clinical Pharmacy (ACCP) Critical Care Practice and Research Network members in 12 geographically diverse states. The questionnaire focused on adults with moderate-severe ARDS (PaO2:FiO2
Date made available2023
PublisherSAGE Journals

Cite this